These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 32340993)
1. Advanced Quantification Methods To Improve the 18b Dormancy Model for Assessing the Activity of Tuberculosis Drugs Pieterman ED; Sarink MJ; Sala C; Cole ST; de Steenwinkel JEM; Bax HI Antimicrob Agents Chemother; 2020 Jun; 64(7):. PubMed ID: 32340993 [TBL] [Abstract][Full Text] [Related]
2. Simple model for testing drugs against nonreplicating Mycobacterium tuberculosis. Sala C; Dhar N; Hartkoorn RC; Zhang M; Ha YH; Schneider P; Cole ST Antimicrob Agents Chemother; 2010 Oct; 54(10):4150-8. PubMed ID: 20679505 [TBL] [Abstract][Full Text] [Related]
3. Activity of Moxifloxacin against Louie A; Duncanson B; Myrick J; Maynard M; Nole J; Brown D; Schmidt S; Neely M; Scanga CA; Peloquin C; Drusano GL Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249693 [TBL] [Abstract][Full Text] [Related]
4. Enhancement of in vitro activity of tuberculosis drugs by addition of thioridazine is not reflected by improved in vivo therapeutic efficacy. de Knegt GJ; ten Kate MT; van Soolingen D; Aarnoutse R; Boeree MJ; Bakker-Woudenberg IA; de Steenwinkel JE Tuberculosis (Edinb); 2014 Dec; 94(6):701-7. PubMed ID: 25621361 [TBL] [Abstract][Full Text] [Related]
5. Bactericidal activity of moxifloxacin on exponential and stationary phase cultures of Mycobacterium tuberculosis. Sulochana S; Mitchison DA; Kubendiren G; Venkatesan P; Paramasivan CN J Chemother; 2009 Apr; 21(2):127-34. PubMed ID: 19423464 [TBL] [Abstract][Full Text] [Related]
6. Assessment of treatment response by colony forming units, time to culture positivity and the molecular bacterial load assay compared in a mouse tuberculosis model. de Knegt GJ; Dickinson L; Pertinez H; Evangelopoulos D; McHugh TD; Bakker-Woudenberg IAJM; Davies GR; de Steenwinkel JEM Tuberculosis (Edinb); 2017 Jul; 105():113-118. PubMed ID: 28610782 [TBL] [Abstract][Full Text] [Related]
7. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship. Tomioka H Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755 [TBL] [Abstract][Full Text] [Related]
8. [Frontier of mycobacterium research--host vs. mycobacterium]. Okada M; Shirakawa T Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793 [TBL] [Abstract][Full Text] [Related]
9. Altered expression of isoniazid-regulated genes in drug-treated dormant Mycobacterium tuberculosis. Karakousis PC; Williams EP; Bishai WR J Antimicrob Chemother; 2008 Feb; 61(2):323-31. PubMed ID: 18156607 [TBL] [Abstract][Full Text] [Related]
10. Vitamin C Potentiates the Killing of Mycobacterium tuberculosis by the First-Line Tuberculosis Drugs Isoniazid and Rifampin in Mice. Vilchèze C; Kim J; Jacobs WR Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29298757 [TBL] [Abstract][Full Text] [Related]
11. Mycobacterium tuberculosis Is Selectively Killed by Rifampin and Rifapentine in Hypoxia at Neutral pH. Iacobino A; Piccaro G; Giannoni F; Mustazzolu A; Fattorini L Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 27993848 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of the BBL MGIT (Mycobacterial growth indicator tube) AST SIRE system for antimycobacterial susceptibility testing of Mycobacterium tuberculosis to 4 primary antituberculous drugs. Bergmann JS; Fish G; Woods GL Arch Pathol Lab Med; 2000 Jan; 124(1):82-6. PubMed ID: 10629136 [TBL] [Abstract][Full Text] [Related]
13. Dormant Mycobacterium tuberculosis converts isoniazid to the active drug in a Wayne's model of dormancy. Raghunandanan S; Jose L; Kumar RA J Antibiot (Tokyo); 2018 Nov; 71(11):939-949. PubMed ID: 30185901 [TBL] [Abstract][Full Text] [Related]
14. Multifaceted remodeling by vitamin C boosts sensitivity of Mycobacterium tuberculosis subpopulations to combination treatment by anti-tubercular drugs. Sikri K; Duggal P; Kumar C; Batra SD; Vashist A; Bhaskar A; Tripathi K; Sethi T; Singh A; Tyagi JS Redox Biol; 2018 May; 15():452-466. PubMed ID: 29413958 [TBL] [Abstract][Full Text] [Related]
15. Effect of drug resistance on the generation of secondary cases of tuberculosis. Burgos M; DeRiemer K; Small PM; Hopewell PC; Daley CL J Infect Dis; 2003 Dec; 188(12):1878-84. PubMed ID: 14673768 [TBL] [Abstract][Full Text] [Related]
16. A Novel Small-Molecule Inhibitor of the Sukheja P; Kumar P; Mittal N; Li SG; Singleton E; Russo R; Perryman AL; Shrestha R; Awasthi D; Husain S; Soteropoulos P; Brukh R; Connell N; Freundlich JS; Alland D mBio; 2017 Feb; 8(1):. PubMed ID: 28196957 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of the ESP culture system II for testing susceptibilities of Mycobacterium tuberculosis isolates to four primary antituberculous drugs. Bergmann JS; Woods GL J Clin Microbiol; 1998 Oct; 36(10):2940-3. PubMed ID: 9738047 [TBL] [Abstract][Full Text] [Related]
18. Investigation of Elimination Rate, Persistent Subpopulation Removal, and Relapse Rates of Mycobacterium tuberculosis by Using Combinations of First-Line Drugs in a Modified Cornell Mouse Model. Hu Y; Pertinez H; Ortega-Muro F; Alameda-Martin L; Liu Y; Schipani A; Davies G; Coates A Antimicrob Agents Chemother; 2016 Aug; 60(8):4778-85. PubMed ID: 27216065 [TBL] [Abstract][Full Text] [Related]
19. In vitro postantibiotic effects of rifapentine, isoniazid, and moxifloxacin against Mycobacterium tuberculosis. Chan CY; Au-Yeang C; Yew WW; Leung CC; Cheng AF Antimicrob Agents Chemother; 2004 Jan; 48(1):340-3. PubMed ID: 14693563 [TBL] [Abstract][Full Text] [Related]